Wealth Preservation Advisors LLC Invests $373,000 in Abbott Laboratories $ABT

Key Points

• Wealth Preservation Advisors LLC made a new investment of approximately $373,000 in Abbott Laboratories, acquiring 2,815 shares during the first quarter of the year.
• Abbott Laboratories reported a quarterly earnings per share (EPS) of $1.26, meeting analyst estimates, with a revenue of $11.14 billion for the quarter.
• Research analysts have generally favorably rated Abbott Laboratories, with a consensus rating of "Moderate Buy" and an average price target of $144.47.

Wealth Preservation Advisors LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,815 shares of the healthcare product maker's stock, valued at approximately $373,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories during the first quarter worth approximately $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories in the first quarter worth approximately $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories in the first quarter worth approximately $30,000. JCIC Asset Management Inc. acquired a new stake in Abbott Laboratories in the first quarter worth approximately $32,000. Finally, Vision Financial Markets LLC acquired a new stake in Abbott Laboratories in the first quarter worth approximately $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ABT shares. Raymond James Financial cut their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Mizuho upped their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 16th. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and upped their target price for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, BTIG Research cut their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $144.47.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by insiders.

Abbott Laboratories Price Performance

Shares of NYSE:ABT traded up $1.22 on Monday, reaching $132.59. 4,430,637 shares of the company traded hands, compared to its average volume of 5,346,421. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company's 50 day moving average is $130.99 and its 200-day moving average is $131.34. The stock has a market capitalization of $230.76 billion, a PE ratio of 16.61, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a $0.59 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.